Get the Stockscreener App
6.66
1.22%
0.08
After Hours:
6.66
Vir Biotechnology Inc stock is traded at $6.66, with a volume of 1.51M.
It is up +1.22% in the last 24 hours and up +29.82% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$6.58
Open:
$6.51
24h Volume:
1.51M
Relative Volume:
1.03
Market Cap:
$926.57M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.699
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+18.29%
1M Performance:
+29.82%
6M Performance:
+22.65%
1Y Performance:
-23.62%
1-Day Range:
$6.51
$6.875
1-Week Range:
$5.60
$7.06
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.66 | 915.44M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.01 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
692.58 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.21 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.41 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.17 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com India
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Nasdaq Index Fund Health Drive - Kalkine Media
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo! Finance Canada
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down After Insider Selling - MarketBeat
What drives Vir Biotechnology Inc stock priceStochastic Oscillator Alerts & You’ve Never Seen Stock Picks Like These - earlytimes.in
Vir Biotechnology director Sato sells $132k in stock By Investing.com - au.investing.com
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology director Sato sells $132k in stock - Investing.com
Vir Biotechnology Director Sells 22,000 Shares - TradingView
Chmn Sato Sells 22,000 ($132.1K) Of Vir Biotechnology Inc [VIR] - TradingView
Endurance (Cayman) Ltd Svf Sells 61,493 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 127,938 Shares of Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.1%What's Next? - MarketBeat
Vir Biotechnology (VIR) Stock Analysis Report | Financials & Insights - Benzinga
Vir Biotechnology Reports Q3 2025 Financial Results and Clinical Progress - MSN
Why analysts remain bullish on Vir Biotechnology Inc. stockJuly 2025 Gainers & Precise Swing Trade Entry Alerts - BỘ NỘI VỤ
Ensign Peak Advisors Inc Increases Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology’s Earnings Call: Achievements and Challenges - MSN
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 227,803 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 235,971 Shares - MarketBeat
Owner SVF Endurance (Cayman) Ltd Sells 463,774 ($2.9M) Of Vir Biotechnology Inc [VIR] - TradingView
SVF Endurance reports Vir (VIR) insider sales around $6 per share - Stock Titan
H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
How to manage a losing position in Vir Biotechnology Inc.Weekly Stock Report & AI Enhanced Trade Execution Alerts - newser.com
Is Vir Biotechnology Inc. stock gaining market shareRisk Management & Long Hold Capital Preservation Tips - newser.com
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - BioSpace
How Vir Biotechnology Inc. stock reacts to job market dataWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
What margin trends mean for Vir Biotechnology Inc. stockMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock - MarketBeat
Will Vir Biotechnology Inc. stock deliver consistent dividendsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutionsJuly 2025 Momentum & Reliable Intraday Trade Alerts - newser.com
What to do if you’re stuck in Vir Biotechnology Inc.Market Trend Summary & Daily Stock Trend Reports - newser.com
How Vir Biotechnology Inc. stock reacts to oil pricesWeekly Volume Report & Target Return Focused Picks - newser.com
Vir Biotechnology EVP O’Byrne sells $37,782 in shares By Investing.com - Investing.com Nigeria
Vir Biotechnology EVP O’Byrne sells $37,782 in shares - Investing.com
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity - Stock Titan
Vir Biotechnology EVP & CFO Jason O'Byrne Sells Shares - TradingView
CFO O'Byrne Surrenders 6,799 Of Vir Biotechnology Inc [VIR] - TradingView
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):